Navigation Links
Shire plc - Statement re ProAmatine
Date:8/17/2010

-->

Shire plc - Statement re ProAmatine

 

PHILADELPHIA, Pennsylvania, August 17, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) acquired ProAmatine as a part of the acquisition of Roberts Pharma in 1999 and Shire conducted and completed the post marketing trials that the FDA required. The FDA, however, viewed these trials as inconclusive and required that additional trials be conducted for ProAmatine to maintain its marketing authorization. As a result, Shire elected to withdraw the product effective September 30, 2010 and notified the FDA in November 2009 and healthcare professionals earlier this year of this decision. Shire's withdrawal of the NDA was not related to any concerns regarding the safety of ProAmatine.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
2. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
3. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
4. Shire plc Appoints Two New Board Directors
5. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
6. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
7. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
8. Shires Replenished Portfolio Drives Excellent Quarterly Performance
9. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
10. Shire Supports Rare Disease Day 2010
11. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
(Date:3/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... platform company serving the global pharmaceutical, biotechnology, and ... New Drug (IND) application for WuXi MedImmune,s novel ... accepted for review by the China Food and ... 2012, MedImmune, the global biologics research and development ...
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
(Date:3/26/2015)... 26, 2015 PAREXEL International Corporation ... clinical research organization , announced today that ... to acquire all of the business assets of ... provider of specialized pharmacovigilance services, based in ... detection, assessment, monitoring, and prevention of adverse ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... TAIAN CITY, China, June 8 /PRNewswire-Asia-FirstCall/ ... ("China Biologic" or the "Company"),one of the leading ... ("PRC"), today announced that the Company has entered ... led by Essence,International Investment Limited, pursuant to which ...
... , Research Published by Scripps Associate Professor Xiang-Lei Yang ... , , SAN DIEGO, June 8 The ... Research Institute (TSRI) News & Views highlights ... Xiang-Lei Yang, a scientific co-founder of aTyr Pharma. ...
... from sediments deep under the Pacific Ocean, could provide ... in the current issue of the journal, Microbiology ... Agricultural University in Wuhan, PR China describe how a ... to be highly effective in removing manganese from solutions, ...
Cached Biology Technology:China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million 2China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million 3China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million 4Scripps Research Institute Highlights Groundbreaking Work of aTyr Pharma Scientific Co-Founder 2
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
(Date:3/18/2015)... 2015 As mobile payments become more ... wallets and apps continue to be introduced into the market ... mobile payment industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... BABA ), Apple Inc. (NASDAQ: AAPL ), ... (NASDAQ: FB ) NXT-ID, Inc. (NASDAQ: ...
(Date:3/17/2015)... Emotient, the leader in facial expression ... availability of Emotient Analytics , the world,s ... facial expressions. The system analyzes videos of people ... services. It delivers audience response metrics - such ... derived from facial evidence of emotional states. Consumer ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... California are declining and, in some cases, moving to higher ... loss of habitat, according to a study authored by biologist ... the College of Science. "Caterpillars are important herbivores as ... Forister said. "They play a significant role in an ecosystem. ...
... and the introduction of new crops relies on a ... change. Basing their argument on evolutionary, ecological, genetic and ... School of Agriculture at the Hebrew University of Jerusalem, ... the likely cause of plant domestication in the Near ...
... Irvine, Calif., Jan. 12, 2010 People with impaired mobility ... limb function long after the injury, if a supplemental protein ... rats. Two new studies by UC Irvine biologists have ... function in rats after a stroke. Administered directly to the ...
Cached Biology News:Climate change and habitat destruction affect butterfly populations 2Stable climate and plant domestication linked 2New stroke therapy successful in rats 2
Human DC-SIGNR/CD209L MAb (Clone 120604)...
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Human SorCS1 Affinity Purified Polyclonal Ab Protein Family: Neurotrophins...
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
Biology Products: